They have entered into an open-access global research partnership with the Structural Genomics Consortium (SGC) to discover and characterise novel drug targets for myeloma. In this first partnership
While there was no statistical difference in viral clearance between treatment and placebo in the overall study population at 12 months, there was a clear separation in 2
This study focused on patients who were at least six months post-stroke with significant functional or neurologic impairment (defined as confined to a wheelchair or required to have
This first-of its kind software solution connects genetic testing, report generation, and clinical care decision-making to accelerate delivery of precision medicine while making it more attainable and affordable.
OrphanDev’s main mission is to accelerate the development of orphan drugs. This collaboration is related to the International pivotal Phase 3 trial of Pharnext’s investigational Pleodrug, PXT-3003, for
The Japan-based company will leverage Medidata’s industry-leading electronic data capture and management technology (Medidata Rave) to evaluate additional indications for OPDIVO, an immunotherapy drug that was initially approved
FDA has now completed its mid-cycle review of the Ameluz® NDA (new drug application). The review resulted in no additional requests for material nor were any additional review
Based on the FDA’s response, XTL plans to file its IND, and in the coming quarters initiate a global clinical trial for hCDR1 in the treatment of systemic
Perrigo was the authorized generic distributor of these products from 2005 to 2013 before the agreement was terminated. Generic and brand sales of Retin-A, which is indicated for
The FDA has assigned a Prescription Drug User Fee Act (PDUFA) action date of November 16, 2016 . The Marketing Authorisation Application (MAA) for brodalumab in psoriasis was
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.